Time filter

Source Type

Lei D.,University of Texas M. D. Anderson Cancer Center | Lei D.,Shandong University | Lei D.,Key Laboratory of Otolaryngology | Sturgis E.M.,University of Texas M. D. Anderson Cancer Center | And 5 more authors.
Cancer Epidemiology Biomarkers and Prevention

Background: Single-nucleotide polymorphisms in the promoter region of the FAS and FASLG may alter the transcriptional activity of these genes. We therefore investigated the association between the FAS and FASLG polymorphisms and risk for second primary malignancy (SPM) after index squamous cell carcinoma of the head and neck (SCCHN). Methods: We used log-rank test and Cox proportional hazard models to assess the association of the four single-nucleotide polymorphisms (FAS -1377 G > A, FAS -670 A > G, FASLG -844 C > T, and FASLG -124 A > G) with the SPM-free survival and SPM risk among 1,286 incident SCCHN patients. Results: Compared with patients having the FAS -670 AA or the FASLG -844 CC genotypes, the patients having variant genotypes of FAS -670 AG/GG or FASLG -844 CT/TT genotypes had significantly increased risk for SPM, respectively. A trend for significantly increased SPM risk with increasing number of risk genotypes of the four polymorphisms was observed in a dose-response manner. Moreover, the patients with three or four combined risk genotypes had an ∼1.8- or 2.5-fold increased risk for developing SPM compared with patients with zero or one risk genotypes, respectively. Conclusions: Our results suggest a modestly increased risk for SPM after index SCCHN with FAS -670 A > G and FASLG -844 C > T polymorphisms and an even greater risk for SPM with multiple combined FAS and FASLG risk genotypes. Impact: The FAS and FASLG polymorphisms may serve as a susceptible marker for SCCHN patients at high SPM risk. ©2010 AACR. Source

Gao Y.,Memorial University of Newfoundland | Liu D.,University of Toronto | Liu D.,Shandong University | Liu D.,Key Laboratory of Otolaryngology
European Archives of Oto-Rhino-Laryngology

The main objective of the meta-analysis was to investigate whether intratympanic steroid injections in combination with systemic steroids would provide an additional advantage over systemic steroid therapy (SST) alone in patients with idiopathic sudden sensorineural hearing loss (ISSNHL). The results will provide a meaningful suggestion in clinical therapy of ISSNHL. The electronic database search was based on the database in OVID Medline, Embase and PubMed up to December 15, 2015 with the goal of identifying all available observational studies examining the effects of combination therapy and SST in ISSNHL patients. Observational studies that compared the pure tone average (PTA) improvement and recovery rate between combination therapy and SST group in ISSNHL patients were selected. Finally we have identified eight eligible studies that focused on comparing the combination therapy and SST in ISSNHL from designated researches. In the PTA improvement group, seven studies have been analyzed to compare the pooled mean differences between two therapy modalities and subgroups based on initial hearing loss and treatment delay. In the recovery rate group, six studies were calculated for pooled risk ratios and subgroup analysis was also conducted. Through our meta-analysis, we have reached the conclusion that combination therapy exhibited better outcomes in PTA improvement than SST alone, especially in severe-profound initial hearing loss cases. Combination therapy also showed advantages in recovery rate. Whether time of treatment delay would influence the PTA improvement and recovery rate requires further researches. © 2016 Springer-Verlag Berlin Heidelberg Source

Summary Our aim of the study was to investigate the precise relationship of repair cross-complementation group 1 (ERCC1) expression and the survival as well as objective response rate to cisplatin-based concurrent chemoradiotherapy (CCRT) and a meta-analysis was conducted to analysis ERCC1's prognostic roles in head and neck cancer. A search based on published articles in PubMed, Embase and CKNI database (up to Oct 15, 2014) to find eligible studies meeting eligibility criteria and then a meta-analysis was conducted to assess the outcomes in head and neck squamous cell carcinomas (HNSCC) patients with different ERCC1 expression. The principle outcomes were hazard ratio (HR) for survival analysis and relative risks (RR) for objective response. Fixed or random model was used for calculation according to the heterogeneity. The results showed that 9 studies involving 568 patients met the inclusion criteria. Low/negative expression of ERCC1 was associated with longer overall survival (OS) and profession-free survival (PFS) after receiving cisplatin-based CCRT therapy (HR 0.38; 95% confidence interval (CI) 0.21-0.63; P < 0.001 and HR 0.37; 95%CI 0.21-0.63; P < 0.001). And there was no significant difference discovered in objective response rate between low/negative and high/positive ERCC1 expression (RR 1.19; 95%CI 1.00-1.43; P = 0.06). Evidence of modest heterogeneity was found between ERCC1 expression and OS (I2 = 48.8%, P < 0.05) and subgroup analysis was performed based on ethnicity, variable methods and primary tumor location. The conclusion is that ERCC1 might be the one of adverse prognostic factors affecting the survival time and objective response to cisplatin-based chemoradiotherap due to its drug-resistance characteristics. © 2015 Elsevier Ltd. Source

Song P.-L.,Harbin Medical University | Song P.-L.,Capital Medical University | Li H.-J.,Harbin Medical University | Wang N.-Y.,Capital Medical University | Wang N.-Y.,Key Laboratory of Otolaryngology
Chinese Medical Journal

Background Many factors interfering with a listener attempting to grasp speech in noisy environments. The spatial hearing by which speech and noise can be spatially separated may play a crucial role in speech recognition in the presence of competing noise. This study aimed to assess whether, and to what degree, spatial hearing benefit speech recognition in young normal-hearing participants in both quiet and noisy environments. Methods Twenty-eight young participants were tested by Mandarin Hearing In Noise Test (MHINT) in quiet and noisy environments. The assessment method used was characterized by modifications of speech and noise configurations, as well as by changes of speech presentation mode. The benefit of spatial hearing was measured by speech recognition threshold (SRT) variation between speech condition 1 (SC1) and speech condition 2 (SC2). Results There was no significant difference found in the SRT between SC1 and SC2 in quiet. SRT in SC1 was about 4.2 dB lower than that in SC2, both in speech-shaped and four-babble noise conditions. SRTs measured in both SC1 and SC2 were lower in the speech-shaped noise condition than in the four-babble noise condition. Conclusion Spatial hearing in young normal-hearing participants contribute to speech recognition in noisy environments, but provide no benefit to speech recognition in quiet environments, which may be due to the offset of auditory extrinsic redundancy against the lack of spatial hearing. Source

Guan X.,University of Texas M. D. Anderson Cancer Center | Guan X.,Nanjing University | Sturgis E.M.,University of Texas M. D. Anderson Cancer Center | Lei D.,University of Texas M. D. Anderson Cancer Center | And 6 more authors.
Clinical Cancer Research

Purpose: Transforming growth factor-β1 (TGF-β1) plays an important role in inflammation and immune responses, which control the human papillomavirus (HPV) clearance and escape of immune surveillance, and may contribute to genetic susceptibility to HPV16 infection. Experimental Design: In this case series study, we analyzed the HPV16 status in tumor specimens and genotyped three TGF-β1 polymorphisms using genomic DNA from the blood of 200 squamous cell carcinoma of the oropharynx (SCCOP) cases. We calculated odds ratio (OR) and 95% confidence intervals (95% CI) in univariate and multivariable logistic regression models to examine the association between the TGF-β1 polymorphisms and HPV16 status in SCCOP. Results: Compared with those with the common homozygous genotype, the TGF-β1 T869C variant genotypes were significantly associated with HPV16-positive tumor status among patients with SCCOP (OR, 1.97; 95% CI, 1.03-3.76), but no significant association was observed for the TGF-β1 C509T or G915C polymorphism. When all variant genotypes were combined, however, SCCOP patients carrying genotypes with any of these TGF-β1 variants were more than twice as likely to have an HPV16-positive tumor (OR, 2.28; 95% CI, 1.16-4.50) as patients with no variant genotypes. The stratified analysis showed that those under 54 years of age, non-Hispanic white patients, never smokers, and never drinkers with any variant TGF-β1 genotypes were also more likely to have HPV16-positive tumors. Conclusions: TGF-β1 polymorphisms may serve as a susceptibility marker for tumor HPV16 status among SCCOP patients, particularly those who were never smokers and never drinkers. Large studies are needed to validate our findings. ©2010 AACR. Source

Discover hidden collaborations